Skip to content

A randomized controlled trial of pulmonary ultrasound guided prophylactic use of diuretics for subclinical heart failure in patients with acute myocardial infarction

A randomized controlled trial of pulmonary ultrasound guided prophylactic use of diuretics for subclinical heart failure in patients with acute myocardial infarction

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2400084523
Enrollment
Unknown
Registered
2024-05-20
Start date
2022-10-31
Completion date
Unknown
Last updated
2024-05-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

acute myocardium infarction

Interventions

Study group:Furosemide
Control group:None

Sponsors

Xuzhou Central Hospital
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1) Patients with acute myocardial infarction within 72 hours of onset with B-line score of 2 or greater and without dyspnea on bedside pulmonary ultrasonography. 2) Age 18-80 3) Sign the informed consent

Exclusion criteria

Exclusion criteria: 1) Severe pulmonary fibrosis, pulmonary infection, pneumonia, acute respiratory distress syndrome (ARDS) and other lung diseases 2) Moderate to severe renal insufficiency patients with creatinine greater than 120umol/L 3) Acute myocardial infarction with severe mechanical complications 4) Cardiogenic shock 5) Severe hypotension (systolic blood pressure less than 90mmHg or 40mmHg decrease from the original systolic blood pressure) 6) Severe valvular disease and congenital heart disease without surgical treatment 7) Any known allergic reaction, hypersensitivity reaction and other contraindications to furosemide 8) Pregnant and lactating women 9) Cancer patients with a predicted survival of less than 1 year 10) Severe mental disorder, unable to express wishes 11) The presence of obvious other abnormal signs, laboratory tests and clinical diseases is not suitable for investigator participation in the judgment of the investigator.

Design outcomes

Primary

MeasureTime frame
Occurrence of symptomatic heart failure (dyspnea);

Secondary

MeasureTime frame
Cardiac arrhythmias during hospitalization;Comorbid pulmonary infection during hospitalization;Changes in blood markers, renal function, creatinine values during hospitalization (at the time of admission and before discharge).;

Countries

China

Contacts

Public ContactLILI

Xuzhou Central Hospital

734337242@qq.com+86 181 6877 8682

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026